Tecovirimat - SIGA Technologies

Drug Profile

Tecovirimat - SIGA Technologies

Alternative Names: Arestvyr; SIGA-246; ST-246 Form I (monohydrate); ST-246 Form V (hemihydrate); ST-246®; Tecovirimat monohydrate - SIGA Technologies; TPOXX

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroPharma
  • Developer Biomedical Advanced Research and Development Authority; SIGA Technologies
  • Class Antivirals; Benzamides; Indoles; Small molecules
  • Mechanism of Action Vaccinia virus p37 protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Smallpox; Orthopoxvirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Smallpox
  • Phase I Orthopoxvirus infections

Most Recent Events

  • 04 Oct 2018 SIGA Technologies establishes CRADA with the United States Army Medical Research Institute of Infectious Disease for the development of tecovirimat in Smallpox
  • 10 Sep 2018 SIGA Technologies signed a contract with BARDA for the development of Tecovirimat for Small-pox (PO, IV)
  • 17 Jul 2018 Preclinical development is ongoing for Smallpox (Adjunctive treatment) (PO, Capsule) (SIGA Pipeline, July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top